TY - JOUR T1 - A prospective evaluation of breast thermography enhanced by a novel machine learning technique for screening breast abnormalities in a general population of women presenting to a secondary care hospital JF - medRxiv DO - 10.1101/2022.11.27.22282737 SP - 2022.11.27.22282737 AU - Richa Bansal AU - Sathiakar Collison AU - Bharat Aggarwal Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/11/30/2022.11.27.22282737.abstract N2 - Objective Artificial intelligence-enhanced breast thermography is being evaluated as an ancillary modality in the evaluation of breast disease. The objective of this study was to evaluate the clinical performance of Thermalytix, a CE-marked, AI-based thermal imaging test, with respect to conventional mammography.Methods A prospective, comparative study performed between 15 December 2018 and 06 January 2020 evaluated the performance of Thermalytix in 459 women with both dense and nondense breast tissue. Both symptomatic and asymptomatic women, aged 30 to 80 years, presenting to the hospital underwent Thermalytix followed by 2-D mammography and appropriate confirmatory investigations to confirm malignancy. The radiologist interpreting the mammograms and the technician using the Thermalytix tool were blinded to the others’ findings. The statistical analysis was performed by a third party.Results A total of 687 women were recruited, of whom 459 fulfilled the inclusion criteria. Twenty-one malignancies were detected (21/459, 4.6%). The overall sensitivity of Thermalytix was 95.24% (95% CI, 76.18-99.88), and the specificity was 88.58% (95% CI, 85.23-91.41). In women with dense breasts (n=168, 36.6%), the sensitivity was 100% (95% CI, 69.15-100), and the specificity was 81.65% (95% CI, 74.72-87.35). Among these 168 women, 37 women (22%) were reported as BI-RADS 0 on mammography; in this subset, the sensitivity of Thermalytix was 100% (95% CI, 69.15-100), and the specificity was 77.22% (95% CI, 69.88-83.50).Conclusion Thermalytix showed acceptable sensitivity and specificity with respect to mammography in the overall patient population. Thermalytix outperformed mammography in women with dense breasts and those reported as BI-RADS 0.Key pointsCompared with mammography as the reference, Thermalytix showed acceptable sensitivity and specificity of 95.24% and 88.58%, respectively, in the overall patient population (N=459).Among women with dense breasts (n=168), 37 women (22%) were reported as BI-RADS 0 (incomplete examination) on mammograms, whereas Thermalytix identified all malignancies.Thermalytix identified all malignancies among premenopausal women and women younger than 50 years of age.Summary Statement Thermalytix, an AI-based thermal imaging tool, showed acceptable sensitivity and specificity when mammography was used as the reference in the overall patient population and in women with dense breast tissue.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by Niramai Health Analytix developer of the Thermalytix systemAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For this prospective cross-sectional study number approval was obtained from Institutional Ethics Committee of Max Super Speciality Hospital, Saket, New DelhiI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsAIArtificial IntelligenceACRAmerican College of RadiologyAUCArea under the curveBI-RADSBreast Imaging Reporting and Data SystemCBEClinical breast examinationLMICsLow-and middle-income countriesPPVPositive-predictive valueNPVNegative-predictive valueROCReceiver operating characteristicRFRandom Forest ER -